Can-Fite BioPharma Ltd.
10 Bareket Street
Kiryat Matalon Petah Tikva, 4951778, Israel
Phone: 972 3 924 1114
http://www.canfite.com

Company Overview: Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company.

- **Novel therapeutic approach –** unique technology for the treatment of liver and inflammatory diseases; addressing multi-billion dollar markets
- **Oral drugs with proven safety and efficacy** - Piclidenoson and Namodenoson are oral drugs, Phase III assets in psoriasis and liver cancer; Namodenoson showed strong efficacy in a Phase II NASH study; Piclidenoson is treating patients with moderate-to-severe COVID-19 in a Phase II study
- **Intellectual property portfolio -** 15 patent families issued and pending to protect different indications
- **Corporate partnerships -** Piclidenoson and Namodenoson have been out-licensed in select territories with ~$20 million received to date and potentially up an additional $130 million plus royalties

Equity Overview (as of September 2021)

NYSE American: CANF
TASE: CFBI
1 ADR = 30 ordinary TASE shares
ADRs Outstanding: ~19 M
Ordinary Shares Outstanding: ~573 M

Analyst Coverage

Aegis Capital Group
Alliance Global Partners
Dawson James
H.C. Wainwright

Platform Technology

Targeting the A3 adenosine receptor, highly expressed in inflammatory and cancer cells. Pipeline drugs are agonists at the receptor and bind only to pathological but not normal body cells. High efficacy and good safety has been proven in Phase II and III clinical studies.



- **A3 Adenosine Receptor (A3AR)**

Out-licensing Deals

CMS 康哲药业	China	Psoriasis, NASH, Liver Cancer
KYONGBO / Chong Kun Dang Pharm.	South Korea	Psoriasis, NASH, Liver Cancer
cipher Pharmaceuticals Inc	Canada	Psoriasis
Gebro Pharma	Spain, Austria & Switzerland	Psoriasis
ewo pharma	Eastern Europe	Psoriasis, NASH, Liver Cancer

Investor Contact: Motti Farbstein, CFO, + 972 3 924 1114

**Sources for market size estimates: Evaluate Pharma, Morningstar, DelveInsight, Deutsche Bank, Grand View Research, Adroit Market Research. Source for Otezla sales Evaluate Pharma*

Drug Development Pipeline



Piclidenoson Clinical Development

- **Phase III Psoriasis – Topline Results Expected Q1 2022**

  Can-Fite completed enrollment of ~400 patients with moderate-to-severe psoriasis in its pivotal Phase III Comfort™ trial based on positive results from an interim analysis of the data. The trial is designed to establish superiority vs. placebo and non-inferiority vs. Otezla®, an oral drug that generated $1.9 B in 2020 sales, projected to be $3.4 B by 2026*.

- **Phase II COVID-19 – Currently Enrolling**

  As an anti-inflammatory and anti-viral drug, Piclidenoson has the potential to treat COVID-19. Under an FDA approved protocol, Can-Fite is enrolling 40 patients in a 28-day Phase II study of Piclidenoson as a potential addition to standard of care in COVID-19 infected patients with moderate-to-severe symptoms.

Namodenoson Clinical Development

- **Pivotal Phase III Study in Liver Cancer – Expected to Commence Q4 2021**

  Can-Fite received agreement from both the FDA and European Medicines Agency (EMA) on the protocol for its pivotal Phase III study for market registration. Namodenoson has Orphan Drug status with both the FDA and EMA, as well as Fast Track Status with the FDA for treatment of hepatocellular carcinoma (HCC). The study will enroll 450 patients and an interim analysis will be conducted after 50% of enrolled patients are treated. Namodenoson will be evaluated as a 2nd or 3rd line treatment for advanced (Child Pugh B7) liver cancer patients, with the primary endpoint of improved overall survival.

- **Phase IIb NASH Study – Enrollment Expected to Commence Q3 2021**

  Namodenoson's Phase IIa NASH/NAFLD study met all efficacy and safety endpoints including anti-inflammatory effects, reduced liver fat content, inhibition of fibrosis, decrease in body weight, and demonstrated an excellent safety profile. Can-Fite expects to commence patient enrollment in its Phase IIb NASH study in Q3 2021. NASH is an unmet medical need projected to become a $35-$40 billion market by 2025.